Bharat Biotech International Ltd announced on Tuesday the launch of Hillchol, an innovative single-strain oral cholera vaccine.
According to a press release from the company, Hillchol (BBV131) was developed by Bharat Biotech under a license from Hilleman Laboratories, which is funded by Merck USA and the Wellcome Trust, to fight cholera.
There is a global demand for over 100 million doses of Oral Cholera Vaccines (OCVs) each year, highlighting their importance in cholera prevention. However, there is a worldwide shortage of OCVs due to the limited number of manufacturers.
Bharat Biotech has set up large-scale production facilities in Hyderabad and Bhubaneswar, with a capacity to produce up to 200 million doses of Hillchol.
The vaccine underwent a comprehensive clinical evaluation process, including a Phase 3 trial, which confirmed its safety, immunogenicity, and non-inferiority to other existing OCVs, demonstrating its potential for widespread public health use.
Hillchol is administered orally in a single-dose respule on day 0 and day 14 and is suitable for individuals over the age of one.
India's Gukesh Dommaraju has made history by becoming the youngest World Chess Champion at 18,…
Delhi NCR is in for heavy rain and bone-chilling cold this week, with a yellow…
Gabriel Enrique Angarita Carrasquero, one of Venezuela's migrants, was finally captured after an almost seven-month…
President-elect Donald Trump intends to rename Denali, Alaska's tallest mountain, to Mount McKinley. He hailed…
Donald Trump dropped a hint for TikTok's survival by mentioning how it played an important…
Elon Musk was not shy about his satire 'Save the Bureaucracy' bill, mocking legislative inefficiency.…